

THE HOUSE OF REPRESENTATIVES
Monday, March 5, 2007

Committee Substitute for
House Bill No. 1373

COMMITTEE SUBSTITUTE FOR HOUSE BILL NO. 1373 - By: SCHWARTZ,
TERRILL, SHELTON AND KERN of the House and JOHNSON (CONSTANCE) of the
Senate.

(Professions and occupations - procedure for certain drug – codification –
effective date)

BE IT ENACTED BY THE PEOPLE OF THE STATE OF OKLAHOMA:

- 1 SECTION 1. NEW LAW A new section of law to be codified in the Oklahoma
2 Statutes as Section 353.31 of Title 59, unless there is created a duplication in numbering,
3 reads as follows:
- 4 A. The Legislature finds that:
- 5 1. Organ transplant patients require significant physician oversight and
6 interaction; and
- 7 2. This same protection should be afforded to immunosuppressive products under
8 the state Medicaid program. Differences in products could result in adverse effects,
9 including death, and physicians should be the decision-makers when choices regarding
10 immunosuppressive products are concerned.
- 11 B. An immunosuppressive drug shall not require prior authorization, step therapy,
12 generic substitution, or quantity limits without express written or oral notification and

1 the documented consent of the practitioner and the patient. For purposes of this
2 subsection, “immunosuppressive drug” means a drug that is used in immunosuppressive
3 therapy to inhibit or prevent activity of the immune system, and is used to prevent the
4 rejection of transplanted organs and tissues. Immunosuppressive drugs shall not include
5 drugs for the treatment of autoimmune diseases or diseases that are most likely of
6 autoimmune origin.

7 SECTION 2. This act shall become effective November 1, 2007.

8 COMMITTEE REPORT BY: COMMITTEE ON PUBLIC HEALTH, dated 03-01-07 - DO
9 PASS, As Amended and Coauthored.